Today's Rundown Featured Story | | | Monday, June 1, 2020 Gilead Sciences has more data to show its antiviral remdesivir can help COVID-19 patients improve, even those with moderate disease. A phase 3 study found five days of remdesivir treatment was 65% more likely to improve patient's clinical status at day 11 compared with standard of care. But the company's stock fell anyway. |
|
|---|
|
| | | Monday, May 25, 2020 Many elective procedures were postponed due to COVID-19, but with the Salesforce Accelerate Elective Procedures solution, providers are able to re-engage patients and reschedule elective procedures. |
|
|---|
|
Top Stories Saturday, May 30, 2020 Major health groups raised alarm following the announcement by President Donald Trump that the U.S. is terminating its relationship with the World Health Organization. Monday, June 1, 2020 The U.S. government has shelled out big money to help develop a possible COVID-19 vaccine and boost manufacturing of COVID-19 drugs stateside. Now, in order to amp up production of its chosen shot hopefuls, the government will enlist a Maryland CDMO to get production quickly up to speed. Monday, June 1, 2020 Eli Lilly has begun dosing COVID-19 patients in a phase 1 trial of its AbCellera-partnered antibody. The initiation of the trial, which happened ahead of schedule, marks the start of a new phase of the response to SARS-CoV-2 in which study subjects will receive drugs designed specifically for the virus. Sunday, May 31, 2020 The FDA is looking to add more tests to its list of authorized, home-based coronavirus diagnostics following its recent green lights for lab testing giant Quest Diagnostics and direct-to-consumer company LetsGetChecked. Monday, June 1, 2020 While much of the focus has been on "flattening the curve" when it comes to COVID-19, experts warn hospitals should be prepared for another potential surge: pent-up demand for deferred care. Monday, June 1, 2020 Cigna is nixing member cost-sharing for primary care, specialty care and behavioral health visits in its Medicare Advantage plans. Monday, June 1, 2020 Emergent Biosolutions scored $628 million in an updated manufacturing deal with BARDA to produce COVID-19 vaccine candidates through 2021. BMS launched its MS drug Zeposia after COVID-related delays. And the WHO rallied against claims that the virus has become less potent. Sunday, May 31, 2020 A national survey of clinical diagnostic laboratories found that more than 85% of respondents have seen shortages of testing supplies that hindered their responses to the COVID-19 pandemic. Monday, June 1, 2020 With the acceleration of consumer and provider adoption of telehealth, a quarter of a trillion dollars in current U.S. healthcare spend could be done virtually, according to a new report. Consulting firm McKinsey estimates that up 20% of all Medicare, Medicaid, and commercial outpatient, office, and home health spend could be done virtually. Monday, June 1, 2020 The financial pressures around COVID-19 are creating a “buzz” among employers about a potential shift to reference-based pricing. Monday, June 1, 2020 Sema4 announced an expanded, formal partnership with the state of Connecticut to provide COVID-19 testing to residents, as well as state employees and first responders. Monday, June 1, 2020 The FDA granted an emergency authorization to Abiomed’s Impella RP heart pump system for COVID-19 patients suffering from right-sided heart failure, including those with a pulmonary embolism. Monday, June 1, 2020 Pfizer has launched a special podcast series to discuss COVID-19 issues. The goal of the miniseries is to offer accurate information and updates on the pandemic with discussion that will include the history of other viral outbreaks, the quest for a vaccine, what to do before a vaccine is available and how companies and people are working together to control the spread. |
|
